NWA
De Nationale Wetenschapsagenda

DARTBAC: Dutch Antimicrobial Resistance Technology development and Biofilm Assessment Consortium

The DARTBAC project will prepare the Netherlands for the time when antibiotics are much less effective in the prevention and eradication of infection due to AntiMicrobial Resistance (AMR).

DARTBAC will, from a material perspective, develop new antimicrobial technologies that are not based on antibiotics to target infection prevention and eradication on implant surfaces, in hard tissues and in soft tissues and assess their safety and efficacy in in vitro and in vivo models. In this way, we are unique yet synergistic with most other initiatives that focus on an antibiotics approach. Collectively, we are bridging the entire knowledge-chain regarding development of new material technologies to combat AMR.

DARTBAC will develop a new workflow based on AOPs of predictive in vitro and in vivo models to test safety and efficacy of newly developed antimicrobial technology in order to shorten the time to market. DARTBAC will enhance the therapeutic efficacy of current antibiotics by combination therapy and we will develop and validate these technologies so that they can be brought to the market within the project timeframe.

Finally, we will maintain awareness of the emerging AMR problem in the Netherlands by informing the general public and HealthCare Practitioners (HCPs). This increased AMR awareness by HCPs, the general public, and healthcare policy makers can speed up acceptance and market introduction of these technologies both nationally and internationally. Moreover, such acceptance will ensure that insurance providers and advisory bodies adopt and reimburse new treatment approaches quicker, thereby accelerating clinical implementation.

A successful DARTBAC project with the combination of these goals and objectives can prevent a rise in infection percentage due to AMR, minimize the effect of AMR in the Netherlands, and work towards a Dutch society that is less dependent on antibiotic therapy for infection, prevention, and treatment.

Dossiernummer
NWA.1292.19.354
Projectleider
prof. dr. J.J.C. Arts
Hoofdorganisatie
Maastricht UMC+
Programma
Onderzoek op Routes door Consortia 2019
Financieringsinstrument
NWA L1
Status
Lopend
Thema
Ziekten en gezondheid
Consortium
Amsterdam University Medical Center (Amsterdam UMC), Delft University of Technology (TU Delft), Eindhoven University of Technology (TU/e), Leiden University Medical Centre (LUMC), Maastricht University (UM-M4i), Maastricht University Medical Center (MUMC+), National Institute for Public Health and the Environment (RIVM), Universitair Medisch Centrum Groningen (UMCG), Universitair Medisch Centrum Utrecht (UMCU), Universiteit van Amsterdam (UVA), B. Braun Aesculap (Germany), BiosparQ, Bonalive Biomaterials Ltd, CAM Bioceramics bv, DSM Biomedical, MadamTherapeutics, OS-1, PCI Biotech, ReumaNederland, Zorginnovaties, Dutch Knowledge Institute Medical Specialists (KIMS), Dutch Orthopaedic Association (NOV), AMR-Insights (AMR)

Onderdeel van route

24 projecten
44 clustervragen
Afbeelding
Patient die gescand wordt

Wij beantwoorden deze vragen

Welke vragen hopen we met dit project te beantwoorden? Deze vragen zijn gegroepeerd in de volgende clustervragen.